Clinical trial · Observational
Predictive Value of Air Pollution and Metabolomics for Gastric Cancer.
The Development and Prognosis of Gastric Cancer Based on Air Pollution and Metabolomics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
As one of the common malignant tumours worldwide, gastric cancer continues to have a high incidence and mortality rate, especially in Asia. Although a large number of studies have focused on its underlying genetic and lifestyle factors, the specific role of environmental factors in gastric cancer development and progression has not been fully elucidated. Air pollution, a growing environmental problem, and its major components such as PM2.5, PM10, and NO2 have been shown to be closely associated with the occurrence and development of many chronic diseases. Recent studies have gradually revealed the association between air pollution and certain cancer types (e.g., lung cancer), but its relationship with gastric cancer remains relatively unexplored. Against this background, the application of metabolomics provides new perspectives and methods to study the association between gastric cancer and environmental factors. Metabolomics is capable of systematically analysing the metabolite composition and changes in individuals under different environmental exposures, revealing the potential effects of environmental factors, such as air pollution, on individual metabolic functions. By combining air pollution data and metabolomics analysis, investigators can deeply explore the role of environmental factors in the occurrence, development and prognosis of gastric cancer, and thus provide a scientific basis for the development of prevention and treatment strategies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancers | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| diagnosed with gastric cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- the gastric cancer group
- description
- Pre-operative gastric cancer diagnosed by pathological biopsy in our clinic.
- interventionNames
- Diagnostic Test: diagnosed with gastric cancer
- label
- the contol group
- description
- Adults with no history of malignancy and willing to participate in this study.
Primary outcomes (1)
- measure
- Rate of postoperative complications
- timeFrame
- From date of surgery until the date of first documented postoperative complication, assessed up to 2 months after surgery.
- description
- Surgical complications was defined as any postoperative complication occurring during the postoperative hospitalisation period.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of gastric cancer confirmed by pathology or cytology; * aged \>18 years; * not received chemotherapy, radiotherapy, targeted therapy or immunotherapy; * post-operative pathological stages other than stage IV, or no liver, lung or other organs as confirmed by CT, MRI, B-ultrasound imaging. Exclusion Criteria: * Patients with systemic diseases such as severe cardiorespiratory insufficiency affecting the choice of treatment regimen; * inappropriate for enrolment as assessed by the investigator; * incomplete clinical data.
References
Publications (0)
Data not yet available